Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ingenol Mebutate for Actinic Cheilitis
NCT03452566Phase 2Withdrawn
- Sponsor
- Instituto Nacional de Câncer José Alencar Gomes da Silva
- Start
- Feb 2020
- Primary completion
- Sep 2021
- Modality
- Peptides, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of ingenol mebutate in actinic cheilitis (AC), sponsored by Instituto Nacional de Câncer José Alencar Gomes da Silva. Primary endpoints: Actinic cheilitis response to treatment at 12 months, Maximum Tolerated Dose and 1 more. Planned start Feb 2020; status: withdrawn.
02
Drugs
ingenol mebutate
03
Conditions
actinic cheilitis (AC)
Beyond the preview
Go deeper on NCT03452566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03452566.